Exagen (XGN) Accumulated Expenses (2018 - 2026)

Exagen has reported Accumulated Expenses for 9 years, with the latest figure at $4.8 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 3.56% year-over-year to $4.8 million; the trailing twelve-month figure through Mar 2026 stood at $4.8 million (down 3.56% YoY), and the FY2025 full-year result was $6.3 million, down 8.52% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $4.8 million, down from $6.3 million in the prior quarter.
• The five-year high for Accumulated Expenses was $7.5 million in Q4 2023, with the low at $4.8 million in Q1 2026.
• Historically, Accumulated Expenses has averaged $6.0 million across 5 years, with a median of $6.0 million in 2024.
• Annual changes were most pronounced in 2022 — Accumulated Expenses declined 21.67% — and 2023, when it jumped 40.85%.
• Exagen's Accumulated Expenses stood at $5.3 million in 2022, then surged by 40.85% to $7.5 million in 2023, then retreated by 8.17% to $6.9 million in 2024, then slipped by 8.52% to $6.3 million in 2025, then dropped by 24.58% to $4.8 million in 2026.
• The last three Accumulated Expenses figures came in at $4.8 million (Q1 2026), $6.3 million (Q4 2025), and $5.7 million (Q3 2025), per Business Quant data.